Janssen has submitted a marketing authorization application to EMA for the approval of a treatment for patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on April 28, 2022 the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the approval of niraparib and abiraterone acetate dual-action tablet plus prednisone for the treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Upon approval, niraparib and abiraterone acetate plus prednisone will be the first dual-action tablet in the European Union specifically targeting HRR gene alterations in mCRPC, according to the company. The combination is intended to be more convenient for patients and thus improve treatment compliance.
Prostate cancer is one of the most common cancers in Europe, with approximately 473,000 patients diagnosed in 2020, according to the company. Up to approximately 30% of patients with mCRPC have HRR gene alterations, which are associated with a worse prognosis compared to those without HRR gene alterations.
“People with prostate cancer harboring BRCA alterations face a more aggressive form of disease with worse outcomes and faster progression, sadly leading to a shorter life expectancy,” commented Professor Gerhardt Attard, primary study investigator and clinician scientist and team leader at University College London Cancer Institute, in a press release. “This submission is an important step towards improving the outcomes for people with metastatic prostate cancer harboring BRCA alterations using a targeted therapy that significantly delays the time to their cancer progressing.”
Source: Janssen
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
2 Commerce Drive
Cranbury, NJ 08512